Cochlear's Outlook Is Unclear Despite Margin Support -- Market Talk
Dow Jones
Apr 23
0039 GMT - Cochlear's decision to cut manufacturing and accelerate restructuring should help support margins, but the outlook remains unclear, according to Macquarie analysts. They are positive on the hearing-implant maker's decision to shrink manufacturing output by more than the fall in sales, telling clients in a note that this will reduce inventory. However, they warn that hearing care has been deprioritized by U.S. consumers and European healthcare systems, and see the risk that weak consumer sentiment could also weigh on processor upgrade volumes. Macquarie cuts its target price 52% to A$115.00 and stays neutral on the stock, which is down 1.1% at A$98.51. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 22, 2026 20:39 ET (00:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.